60 Degrees Pharmaceuticals
SXTPNASDAQUSD
- — Source valuation snapshot. Not a live recalculation.
- — Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- — Diluted earnings per share from the latest filed annual.
- $0.53 Prior regular-session close from the quote source.
- $0.49–$0.52 Regular-session low and high so far today.
- 71.9K Regular-session shares traded · Nov 11, 12:32 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $0.48–$8.62 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own SXTP if it converts early commercial revenue into scalable, positive-margin product sales while avoiding repeated dilutive financings that erase per-share economics.
SXTP price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
The company lacks sufficient liquidity to fund current operating burn from existing cash well beyond the next year; therefore the business is dependent on new financing or near-term commercially sizable revenue to continue operations.StrengtheningMateriality: High
Cash decreased from $2,142,485 (2023) to $1,659,353 (2024) to $1,510,065 (2025). If true, shareholders face dilution risk or transaction risk; if false (company secures non-dilutive income or achieves positive operating cash flow) the equity can capture organic upside from revenue growth.
Watch: A material non-dilutive licensing milestone or partnership payment that meaningfully increases cash.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash decreased from $2,142,485 (2023) to $1,659,353 (2024) to $1,510,065 (2025).
Open source ↗Revenue growth from 2022 to 2025 shows the company is able to generate commercial receipts; if that growth continues and is not one-off or customer-concentrated, the business can leverage fixed costs to improve operating leverage.HoldingMateriality: High
Revenue rose from $223,208 (FY2022) to $253,573 (FY2023) to $607,574 (FY2024) to $1,005,471 (FY2025). Continued organic revenue growth is the only sustainable way to eliminate repeat dilution and create equity value from operations.
Watch: Loss of a major customer or contract (if revenue is concentrated) or one-time contract revenue not repeatable.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Revenue rose from $223,208 (FY2022) to $253,573 (FY2023) to $607,574 (FY2024) to $1,005,471 (FY2025).
Open source ↗Gross profit turned positive in 2024 and remained roughly flat in 2025, indicating that unit economics can be positive; however, unless gross margin percent stabilizes or expands as revenue grows, scale will not translate into operating profits.HoldingMateriality: Medium
Gross profit: -$220,977 (FY2023) → $222,809 (FY2024) → $223,776 (FY2025), i.e., a move from negative to sustained positive gross profit. Positive unit economics are necessary (but not sufficient) for eventual profitability; if gross margin deteriorates with scale, revenue growth will not cure losses.
Watch: Gross_profit remaining flat while revenue rises (observed 2024→2025) — indicates COGS rising faster than revenue or price pressure.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Gross profit: -$220,977 (FY2023) → $222,809 (FY2024) → $223,776 (FY2025), i.e., a move from negative to sustained positive gross profit.
Open source ↗Operating losses have narrowed from 2024 to 2025 but remain large in absolute terms versus revenue; the company must either materially cut SG&A/R&D spending or generate substantially higher revenue to reach operating breakeven.StrengtheningMateriality: Medium
Operating income improved from -$9,715,181 (FY2024) to -$7,758,579 (FY2025). Sustained operating losses mean ongoing cash burn and dependency on financing; operating-income improvement is required for long-term equity value.
Watch: Management increases R&D or commercialization spend faster than revenue growth (e.g., larger trials, marketing launches), which would widen operating losses.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating income improved from -$9,715,181 (FY2024) to -$7,758,579 (FY2025).
Open source ↗The large improvement in diluted EPS between 2024 and 2025 is driven more by capital-structure changes (share count or accounting items) than by proportionate net-income improvement, implying per-share recovery depends on controlling dilution or materially improving net income.StrengtheningMateriality: Medium
EPS diluted improved from -$74.17 (FY2024) to -$11.73 (FY2025) while net income improved only modestly (net income -$7,947,107 → -$7,365,158). If EPS improvement is from dilution management, shareholders need real earnings growth to recover intrinsic per-share value; repeated dilutive financings would neutralize nominal EPS improvements.
Watch: If future EPS improvement is driven by sustained profit improvement (net income moving toward positive) rather than dilution, the claim is weakened.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
EPS diluted improved from -$74.17 (FY2024) to -$11.73 (FY2025) while net income improved only modestly (net income -$7,947,107 → -$7,365,158).
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The company lacks sufficient liquidity to fund current operating burn from existing cash well beyond the next year; therefore the business is dependent on new financing or near-term commercially sizable revenue to continue operations. If true, shareholders face dilution risk or transaction risk; if false (company secures non-dilutive income or achieves positive operating cash flow) the equity can capture organic upside from revenue growth.
Revenue growth from 2022 to 2025 shows the company is able to generate commercial receipts; if that growth continues and is not one-off or customer-concentrated, the business can leverage fixed costs to improve operating leverage. Continued organic revenue growth is the only sustainable way to eliminate repeat dilution and create equity value from operations.
Gross profit turned positive in 2024 and remained roughly flat in 2025, indicating that unit economics can be positive; however, unless gross margin percent stabilizes or expands as revenue grows, scale will not translate into operating profits. Positive unit economics are necessary (but not sufficient) for eventual profitability; if gross margin deteriorates with scale, revenue growth will not cure losses.
Operating losses have narrowed from 2024 to 2025 but remain large in absolute terms versus revenue; the company must either materially cut SG&A/R&D spending or generate substantially higher revenue to reach operating breakeven. Sustained operating losses mean ongoing cash burn and dependency on financing; operating-income improvement is required for long-term equity value.
The large improvement in diluted EPS between 2024 and 2025 is driven more by capital-structure changes (share count or accounting items) than by proportionate net-income improvement, implying per-share recovery depends on controlling dilution or materially improving net income. If EPS improvement is from dilution management, shareholders need real earnings growth to recover intrinsic per-share value; repeated dilutive financings would neutralize nominal EPS improvements.
All standing thesis claims
Original report summary
it converts early commercial revenue into scalable, positive-margin product sales while avoiding repeated dilutive financings that erase per-share economics.
BULL CASE / BEAR CASE
Bull case and bear case for 60 Degrees Pharmaceuticals
Where the evidence on 60 Degrees Pharmaceuticals stands: Holding on the latest evidence (Nov 6, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
The company lacks sufficient liquidity to fund current operating burn from existing cash well beyond the next year; therefore the business is dependent on new financing or near-term commercially sizable revenue to continue operations.
Revenue growth from 2022 to 2025 shows the company is able to generate commercial receipts; if that growth continues and is not one-off or customer-concentrated, the business can leverage fixed costs to improve operating leverage.
Gross profit turned positive in 2024 and remained roughly flat in 2025, indicating that unit economics can be positive; however, unless gross margin percent stabilizes or expands as revenue grows, scale will not translate into operating profits.
Operating losses have narrowed from 2024 to 2025 but remain large in absolute terms versus revenue; the company must either materially cut SG&A/R&D spending or generate substantially higher revenue to reach operating breakeven.
The large improvement in diluted EPS between 2024 and 2025 is driven more by capital-structure changes (share count or accounting items) than by proportionate net-income improvement, implying per-share recovery depends on controlling dilution or materially improving net income.
Bear case: what would count against it
A material non-dilutive licensing milestone or partnership payment that meaningfully increases cash.
Loss of a major customer or contract (if revenue is concentrated) or one-time contract revenue not repeatable.
Gross_profit remaining flat while revenue rises (observed 2024→2025) — indicates COGS rising faster than revenue or price pressure.
Thesis-Break Engine
Thesis-break watch · 60 Degrees Pharmaceuticals
No break has crossed 60 Degrees Pharmaceuticals’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MIXEDOther material event.
60 Degrees Pharmaceuticals filed an SEC 8-K on 2026-10-27: Other material event. It is a dated development that tests the current thesis.
- MIXEDRegulation FD disclosure.
60 Degrees Pharmaceuticals filed an SEC 8-K on 2026-10-23: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MIXEDRegulation FD disclosure.
60 Degrees Pharmaceuticals filed an SEC 8-K on 2026-10-06: Regulation FD disclosure. It is a dated development that tests the current thesis.
RISKS / FALSIFIERS
What could break the thesis
- A material non-dilutive licensing milestone or partnership payment that meaningfully increases cash.
- Loss of a major customer or contract (if revenue is concentrated) or one-time contract revenue not repeatable.
- Gross_profit remaining flat while revenue rises (observed 2024→2025) — indicates COGS rising faster than revenue or price pressure.
- Management increases R&D or commercialization spend faster than revenue growth (e.g., larger trials, marketing launches), which would widen operating losses.
- If future EPS improvement is driven by sustained profit improvement (net income moving toward positive) rather than dilution, the claim is weakened.
SXTP news
Loading headlines…
FINANCIAL STATEMENTS
SXTP income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
SXTP: quick answers
- What is SXTP's short interest?
- As of October 30, 2026, 255,088 SXTP shares were sold short, 7.25% of its shares outstanding, up 88.4% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. SXTP short interest history